Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adult Acute Lymphoblastic Leukemia in Complete Remission: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Adult Acute Lymphoblastic Leukemia in Complete Remission: 2 US clinical trials tracked, none currently recruiting.
Adult Acute Lymphoblastic Leukemia in Complete Remission is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition adult-acute-lymphoblastic-leukemia-in-complete-remission
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Adult Acute Lymphoblastic Leukemia in Complete Remission has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adult Acute Lymphoblastic Leukemia in Complete Remission on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adult Acute Lymphoblastic Leukemia in Complete Remission is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01424982
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03192397
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Adult Acute Lymphoblastic Leukemia in Complete Remission records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adult Acute Lymphoblastic Leukemia in Complete Remission trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adult Acute Lymphoblastic Leukemia in Complete Remission page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Adult Acute Lymphoblastic Leukemia in Complete Remission trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Roswell Park Cancer Institute sponsors the most Adult Acute Lymphoblastic Leukemia in Complete Remission trials on record, review their full trial history before evaluating a specific study. See Roswell Park Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adult Acute Lymphoblastic Leukemia in Complete Remission condition card totals 2 registered trials; most-linked intervention Cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.